Log In
Print
BCIQ
Print
Print this Print this
 

BMS-986202 (formerly AM152)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionOral lysophosphatidic acid receptor 1 (LPAR1; (EDG2) antagonist
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1)
Mechanism of ActionLysophosphatidic acid receptor 1 (LPAR1) (EDG2) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF); Treat lung fibrosis of scleroderma and idiopathic pulmonary fibrosis (IPF); Treat pulmonary fibrosis
Regulatory Designation

U.S. - Orphan Drug (Treat idiopathic pulmonary fibrosis (IPF))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today